CRISPR Therapeutics AG (CRSP)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more
What's happening with CRSP?
Powered by Yahoo ScoutCRISPR Therapeutics is poised for potential growth in late 2026 due to expanded approval of its gene-editing therapy Casgevy and anticipated clinical data. Recent earnings showed improved revenue and a narrower loss, yet the stock faces mixed valuation amid ongoing biotech risks.
- Previous Close
56.49 - Open
56.06 - Bid --
- Ask --
- Day's Range
55.35 - 57.21 - 52 Week Range
44.12 - 78.48 - Volume
-- - Avg. Volume
-- - Market Cap (intraday)
5.394B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Recent News
Statistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (5yr expected)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
--
-
Return on Assets (ttm)
--
-
Return on Equity (ttm)
--
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
--
-
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
-
Total Cash (mrq)
--
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
--
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
